Compare RMCO & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | FEMY |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 51.5M |
| IPO Year | N/A | 2021 |
| Metric | RMCO | FEMY |
|---|---|---|
| Price | $2.38 | $0.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 71.5K | ★ 1.9M |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,798,352.00 | $2,061,502.00 |
| Revenue This Year | $531.90 | $64.02 |
| Revenue Next Year | $200.00 | $147.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 445.90 | 63.53 |
| 52 Week Low | $0.91 | $0.31 |
| 52 Week High | $4.76 | $1.80 |
| Indicator | RMCO | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 53.08 |
| Support Level | $2.32 | $0.79 |
| Resistance Level | $2.61 | $0.91 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 49.04 | 34.37 |
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.